Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 12, 2009, Pages 1681-1688

  Johnston, Thomas P ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Atherogenic dyslipidaemia; Biomarker; Coronary artery disease; Poloxamer 407; Soluble cell adhesion molecules

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; POLOXAMER; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; DISEASE MODELS, ANIMAL; E-SELECTIN; HYPERLIPIDEMIAS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED C57BL; POLOXAMER; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 75749140164     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.12.0014     Document Type: Article

References (64)

1. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316.
2. Executive summary of the third report on the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
3. van Vlijmen BJ, Herz J. Gene targets and approaches for raising HDL. Circulation 1999; 99: 12-14.
4. Sirtori CR et al. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 1999; 142: 29-40.
5. Kume N et al. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138-1144.
6. De Caterina R et al. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994; 14: 1829-1836.
7. Khan BV et al. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995; 95: 1262-1270.
8. Cockerill GW et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-1994.
9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Jang Y et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1600.
11. Li H et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
12. Nakashima Y et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerotic-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842-851.
13. Davies MJ et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-229.
14. O'Brien KD et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-682.
15. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
16. Nakai K et al. Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in human atherosclerotic aorta. Coron Artery Dis 1995; 6: 497-502.
17. Wallen NH et al. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 20: 1039-1043.
18. Blan AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-154.
19. Hwang SJ et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225.
20. Hackman A et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-1338.
21. Abe Y et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998; 18: 723-731.
22. Roep BO et al. Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet 1994; 343: 1590-1593.
23. Ridker PM et al. Plasma concentrations of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
24. Ridker PM. Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease. Eur Heart J 1998; 19: 1119-1121.
25. Blankenberg S et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-1342.
26. Takei A et al. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis 2001; 154: 79-86.
27. Dardik R et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000; 83: 338-344.
28. O'Byrne D et al. Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 2001; 50: 207-215.
29. Jeng JR et al. Oxidized low-density lipoprotein enhances monocyte-endothelial cell binding against shear-stress-induced detachment. Biochim Biophys Acta 1993; 1178: 221-227.
30. Cominacini L et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 1997; 22: 117-127.
31. Shih PT et al. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest 1999; 103: 613-625.
32. Palmer WK et al. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998; 136: 115-123.
33. Johnston TP, Zhou X. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. J Cardiovasc Pharmacol 2007; 49: 246-252.
34. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-1042.
35. Johnston TP et al. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J Cardiovasc Pharmacol 1999; 34: 831-842.
36. Johnston TP. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol 2004; 43: 595-606.
37. Johnston TP et al. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 2001; 229: 75-86.
38. Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPARγ activity after administration of poloxamer 407 to mice. Can J Physiol Pharmacol 2008; 86: 643-649.
39. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-479.
40. Allain CA et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-476.
41. Bachorik PS, Albers JJ. Precipitation methods for quantitation of lipoproteins. Methods Enzymol 1986; 129: 78-100.
42. Li C et al. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J Pharm Biomed Anal 1996; 14: 659-666.
43. Snedecor GW, Cochran WG. Tests of hypotheses. In: Snedecor GW, Cochran WG, eds. Statistical Methods. Ames: Iowa State University Press, 1980: 64-82.
44. Johnston TP, Waxman DJ. The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα. J Pharm Pharmacol 2008; 60: 753-759.
45. Johnston TP et al. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 404-411.
46. Johnston TP et al. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000; 149: 303-313.
47. Blankenberg S et al. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
48. Peter K et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512.
49. De Caterina R et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2646-2654.
50. Lupattelli G et al. Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism 2003; 52: 1191-1195.
51. Verna L et al. In vivo low-density lipoprotein exposure induces intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 correlated with activator protein-1 expression. Arterioscler Thromb Vasc Biol 2006; 26: 1344-1349.
52. Bro S et al. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 2004; 15: 1495-1503.
53. Cybulsky MI et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255-1262.
54. Nageh MF et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1517-1520.
55. Collins RG et al. P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 191: 189-194.
56. Iiyama K et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
57. Mellwig KP et al. Improvement of coronary vasodilation capacity through single LDL apheresis. Atherosclerosis 1998; 139: 173-178.
58. Leung WH et al. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.
59. Miyazaki A et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1882-1888.
60. Li D et al. Inhibition of arterial thrombus formation by apoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19: 378-383.
61. Stein Y, Stein O. Does therapeutic intervention achieve slowing of progression or bona fide regression of atherosclerotic lesions? Arterioscler Thromb Vasc Biol 2001; 21: 183-188.
62. Chiesa G et al. Recombinant apolipoprotein A-I (Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002; 90: 974-980.
63. Navab M et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-296.
64. Johnston TP et al. Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages. Mediators Inflamm 2003; 12: 147-155.